Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
RESEARCH TOOLSreports
Holding AVTX?
Track your performance easily
AVTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.95 - $52.56
Previous Close$9.18
Volume4.74K
Average Volume (3M)17.34K
Market Cap
$89.53M
Enterprise Value-$4.38M
Total Cash (Recent Filing)$93.43M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Nov 06, 2024EPS Estimate
-$1.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-192.23
Shares Outstanding9,682,374
10 Day Avg. Volume10,313
30 Day Avg. Volume17,340
Standard Deviation0.59
R-Squared0.00882
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-6.51
Price to Sales (P/S)113.00
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-18.56
Enterprise Value/Gross Profit-6.84
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$35.00Price Target Upside279.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Avalo Therapeutics News
PremiumCompany Announcements
Avalo Therapeutics Shareholders Back Board and Strategies
PremiumCompany Announcements
Avalo Therapeutics Welcomes New CMO with Competitive Package
Ownership Overview
90.86%
Insiders
1.52% Mutual Funds
2.29% Other Institutional Investors
5.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AVTX FAQ
What was Avalo Therapeutics’s price range in the past 12 months?
Avalo Therapeutics lowest stock price was $3.95 and its highest was $52.56 in the past 12 months.
What is Avalo Therapeutics’s market cap?
Currently, no data Available
When is Avalo Therapeutics’s upcoming earnings report date?
Avalo Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Avalo Therapeutics’s earnings last quarter?
Avalo Therapeutics released its earnings results on Aug 12, 2024. The company reported -$14.07 earnings per share for the quarter, missing the consensus estimate of -$6.7 by -$7.37.
Is Avalo Therapeutics overvalued?
According to Wall Street analysts Avalo Therapeutics’s price is currently Undervalued.
Does Avalo Therapeutics pay dividends?
Avalo Therapeutics does not currently pay dividends.
What is Avalo Therapeutics’s EPS estimate?
Avalo Therapeutics’s EPS estimate is -$1.45.
How many shares outstanding does Avalo Therapeutics have?
Avalo Therapeutics has 9,700,000 shares outstanding.
What happened to Avalo Therapeutics’s price movement after its last earnings report?
Avalo Therapeutics reported an EPS of -$14.07 in its last earnings report, missing expectations of -$6.7. Following the earnings report the stock price went down -7.303%.
Which hedge fund is a major shareholder of Avalo Therapeutics?
Currently, no hedge funds are holding shares in AVTX
---
Avalo Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (279.20% Upside)
$35.00 (279.20% Upside)
Blogger Sentiment
Bullish
AVTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
346.90%
Trailing 12-Months
Company Description
Avalo Therapeutics
Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders. It products include CERC-301, CERC-501, CERC-611, and CERC-406. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher and Solomon H. Snyder on January 31, 2011 and is headquartered in Baltimore, MD.
---
AVTX Stock 12 Month Forecast
Average Price Target
$35.00
▲(279.20% Upside)
Technical Analysis
Eloxx Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering AVTX
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-39.74%
reiterated a buy rating last month
Copying Leland Gershell's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -39.74% per trade.
---